Immutep to Participate in Two Upcoming Investor Conferences

SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, and Deanne Miller, COO, will participate in two upcoming investor conferences.

Event:                Cantor Fitzgerald’s Oncology, Hematology & HemeOnc ConferenceDate:                 Wednesday, September 28, 2022Time:                 1:45 PM ETFormat:             Panel Discussion and 1X1 MeetingsPanel:                Trends and Challenges in Immuno-Oncology                            Event:                Ladenburg Thalmann Healthcare Conference:Date:                 Thursday, September 29, 2022Time:                 2:30 PM ETFormat:             Presentation and 1X1 Meetings

A live webcast of Mr. Voigt’s presentation at the Ladenburg Thalmann Healthcare Conference will be available here and after the meeting under the Events page within the Investors & Media section of Immutep’s website.

About ImmutepImmutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep’s lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; [email protected]

U.S. Media:Tim McCarthy, LifeSci Advisors+1 (917) 679 9282; [email protected]

 

Source: Immutep Limited

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ARGUS Assist named CRE Analytics Innovation of the Year at the 2026 PropTech Breakthrough Awards
• InventHelp Inventor Develops New Can Cleaner (MBQ-948)
• Expert Electrician Zachary Bobersky Outlines How Lighting Transforms a Home, Inside and Out, for HelloNation